Entrada Therapeutics (TRDA)
(Real Time Quote from BATS)
$15.57 USD
+0.01 (0.06%)
Updated Jul 10, 2024 12:30 PM ET
1-Strong Buy of 5 1
C Value A Growth B Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TRDA 15.57 +0.01(0.06%)
Will TRDA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TRDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRDA
Strength Seen in Travere (TVTX): Can Its 8.8% Jump Turn into More Strength?
Best Momentum Stocks to Buy for July 9th
TRDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies
New Strong Buy Stocks for July 9th
Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet
Other News for TRDA
Entrada Therapeutics’ ENTR-601-44 Shows Promising Phase 1 Results for DMD, Earns Buy Rating
Entrada Therapeutics price target lowered by $2 at H.C. Wainwright, here's why
Entrada Therapeutics announces $100M registered direct offering
Entrada Therapeutics Announces $100 Million Registered Direct Offering
Entrada to sell 3.37M shares at $14.85 in registered direct offering